Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...

The sum of scalar quantities can be found by adding their values together.

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Adstiladrin showed a 53% CR rate at three months in its pivotal trial, although, that fell to 24% at 12 months, while Anktiva's efficacy was very close to TAR-200, with an initial rate of 84% that ...